🔎 Trials Near Me

Home › Multiple Myeloma › NCT07740317

Neurocognitive Trajectories After BCMA CAR-T

RecruitingObservational study

Longitudinal Neurocognitive Trajectories After BCMA CAR-T in Multiple Myeloma

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

1. Ability to understand and willingness to sign an IRB-approved informed consent
2. Ability to retain independent decision-making capacity as per the enrolling investigator
3. Age ≥ 18 years of age at the time of consent
4. Scheduled to receive BCMA CAR-T therapy for RRMM as confirmed by the treating clinician
5. Ability to read and understand the English language
6. ECOG 0-2
7. If actively taking benzodiazepine, must be able to hold for 3 hours prior to study assessments as per treating clinician
8. Reliable access to internet access; a tablet, laptop and/or desktop computer with a camera; or willingness to come into the clinic to conduct study procedures as outlined in the Study Calendar- as per participant self-report
9. Ability to complete required assessments, as determined by the treating clinician

Exclusion Criteria:

1. Active central nervous system (CNS) disease
2. Known neurodegenerative disease or major neurocognitive disorder
3. Stroke and/or traumatic brain injury (TBI) within 12 months
4. Concurrent investigational neuroactive drugs

About the study

The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).

What is being tested

Sponsor: Wake Forest University Health Sciences · Participants: 50 · Started: 2026-11

Contact the study team

Official record on ClinicalTrials.gov — NCT07740317

Locations in the U.S.

North CarolinaAtrium Health Levine Cancer, Charlotte

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.